Table 1.
Demographic and clinical characteristics of Parkinson’s disease Biomarkers Program (PDBP) participants.
| Characteristic | HC (n = 50) | PD (n = 48) | PSP (n = 40) |
P valuea (HC/PD) |
P valuea (HC/PSP) |
P valuea (PD/PSP) |
|---|---|---|---|---|---|---|
| Age, mean (SD) [95% CI], years | 69 (6) [68–71] | 70 (6) [68–72] | 70 (7) [68–72] | 0.91 | 0.97 | 0.89 |
| Age of onset, mean (SD) [95% CI], years | N.A. | 64 (8) [60–66] | 68 (8) [65–70] | N.A. | N.A. | 0.02 |
| Female/male, No. (%male) | 25/25 (50) | 25/23 (48) | 20/20 (50) | 0.90b | 0.90b | 0.90b |
| Disease duration, median (range), years | N.A. | 6.3 (0.17–25) | 2.5 (0.17–9.2) | N.A | N.A | <0.0001 |
| Hoehn & Yahr stage, mean (SD) | 0.10 (0.36) | 2.04 (0.96) | 2.35 (1.81) | <0.0001 | <0.0001 | 0.34 |
| MDS-UPDRS total, mean (SD) [95% CI] | 6.48 (6.6) [4.5–8.3] | 50.33 (41.3) [3.3–62.3] | 57.23 (33.5) [46.5–67.9] | <0.0001 | <0.0001 | 0.39 |
| MDS-UPDRS part III | 4.58 (5.8) [2.92–6.24] | 33.60 (22.2) [27.1–40.1] | 46.93 (18.4) [41.0–52.8] | <0.0001 | <0.0001 | 0.0028 |
| MoCA, mean (SD) [95% CI] | 26.20 (2.1) [25.6–26.8] | 23.11 (3.6) [22–24.2] | 20.32 (4.9) [18.6–21.9] | <0.0001 | <0.0001 | 0.006 |
Abbreviations: CI, 95% confidence interval; HC, healthy controls; MoCA, Montreal Cognitive Assessment; MDS-UPDRS, Unified Parkinson’s Disease Rating Scale; PD, Parkinson’s disease; PSP, progressive supranuclear palsy; SD, standard deviation; y, years. aBased on a Student t-test. bBased on chi-square test (X2).